Published in final edited form as:

J Rheumatol. 2012 January ; 39(1): 46–53. doi:10.3899/jrheum.110548.

Sex Differences in Response to Anti-TNF Therapy in Early and Established Rheumatoid Arthritis – Results from the Longitudinal Danish DANBIO Registry

Damini Jawaheer, Ph.D.¹, Jørn Olsen, M.D., Ph.D.^{2,3}, and Merete Lund Hetland, M.D., Ph.D., D.M.Sc.⁴ on behalf of all departments of rheumatology in Denmark*

¹Children's Hospital Oakland Research Institute, 5700 Martin Luther King Jr. Way Oakland, California, U.S.A.

²School of Public Health, University of California Los Angeles, 650 Charles E. Young Drive South, Los Angeles, CA 90095, U.S.A.

³School of Public Health, University of Aarhus, Bartholins Allé 2, Building 1260, DK-8000 Aarhus C, Denmark

⁴DANBIO Registry, Department of Rheumatology, Copenhagen University Hospital at Glostrup, Copenhagen, Denmark

Abstract

Objective—To investigate sex differences in response to anti-tumor necrosis factor (TNF) therapy over time in early versus established rheumatoid arthritis (RA).

Methods—RA patients who initiated anti-TNF therapy between January 2003 and June 2008 in Denmark were selected from the DANBIO Registry. Sex differences in baseline disease features were examined using Chi-square, Mann-Whitney and t-tests. Using a generalized estimating equations (GEE) model for repeated measures, we examined EULAR responses in men and women over 48 months of follow up, adjusting for baseline values of age, disease activity (DAS28), disease duration and anti-TNF, methotrexate and prednisolone use.

Results—At initiation of anti-TNF therapy (baseline), 328 women and 148 men had early RA (< 2 years), and 1,245 women and 408 men had established RA (>2 years). In both early and established RA, men and women had active disease with similar DAS28 scores (mean±SD: 5.2±1.1), physician global scores, swollen joint counts and radiographic changes. In early RA, men were significantly more likely to achieve a EULAR good/moderate response over 48 months compared to women (GEE: p=0.003), and a significant interaction between sex and follow up time (GEE: p<0.0005) suggested that men achieved this response sooner than women.

Conclusion—Better responses to anti-TNF therapy among men compared to women in early but not established RA suggest that disease duration at initiation of therapy may be an important factor to consider when investigating sex differences in treatment responses.

* All departments are listed in the acknowledgements

Address for reprints: Dr. D Jawaheer, Children's Hospital Oakland Research Institute (CHORI), 5700 Martin Luther King Jr. Way, Oakland, CA 94609-1609, USA; djawaheer@chori.org

Disclosures:

D. Jawaheer: None

J. Olsen: None

M.L. Hetland: None

Key Indexing Terms

Rheumatoid arthritis; Sex; Anti-TNF response

Introduction

It is well-established that there is a strong sex bias in the occurrence of rheumatoid arthritis (RA), with women being affected at least 3 times more often than men (1). Sex differences in RA outcomes including disease activity and functional capacity in early (2, 3) as well as longstanding disease (4–6) have been described, though not yet established. Furthermore, over the last few years, a uniform trend appears to be emerging from studies that examined sex as a potential predictor of remission in RA – increased remission rates in response to conventional as well as biologic disease modifying anti-rheumatic drugs (DMARDs) have been consistently observed among men compared to women (2, 7–13).

There seems to be a consensus among recent studies of early RA that in the early stages of the disease, disease activity measures are similar between men and women, and over time, women have a worse disease course than men despite similar treatment (2, 3, 14–16); hence, men are more likely to achieve better responses. Thus, in early RA, sex differences in treatment outcomes only become apparent as the disease evolves. It has not yet been investigated whether the sex differences in treatment responses observed in early RA are also present when treatment is initiated two or more years after diagnosis, i.e. in patients with established RA. Studies of RA patients with variable disease durations that examined the influence of sex on treatment responses have yielded conflicting findings (13, 17), and did not address the possible role of RA duration at the start of treatment.

In the present study, we specifically investigated whether the duration of RA when anti-TNF therapy was started, i.e. early RA (< 2 years since diagnosis) vs. established RA (>2 years since diagnosis), influenced treatment responses differently among men compared to women. To address this question, we examined sex differences in European League Against Rheumatism (EULAR) responses over 48 months of follow up in a large prospective cohort of RA patients from the national DANBIO Registry in Denmark (18) from the time the patients initiated anti-TNF therapy.

Methods

Patients

RA patients throughout Denmark are enrolled in the observational DANBIO registry when they are first prescribed biologic treatment (18). For the present study, RA patients who initiated anti-TNF therapy (adalimumab, etanercept or infliximab) for the first time, from 1 January 2003 to 30 June 2008, were selected from the DANBIO Registry. All patients satisfied the 1987 American College of Rheumatology (ACR) criteria for RA (19). As mandated by Danish law, DANBIO was approved by the Danish Data Registry, and by the National Board of Health, and written informed consent was not required.

Data Collected

All patients were examined by rheumatologists at the time when biologic therapy was first prescribed (study baseline), and approximately every 6 months thereafter. Clinical and demographic data from each of these time-points, as well as data for prescription and outcomes for anti-TNF and other therapies used were stored in the DANBIO Registry. For the present study, data available at each 6-month interval were used for the analyses for a

total follow up time of 48 months. These included 28-joint counts for tender (TJC28) and swollen joints (SJC28), as well as self-reported measures such as the patient global health (GH). Blood samples drawn at baseline and at each follow up were used to evaluate levels of C-reactive protein (CRP). It should be noted that since DANBIO is a national Registry mandated by Danish Law, all subjects enrolled should remain in the database for as long as they continue to obtain treatment in hospital rheumatology departments in Denmark. Therefore, in principle, there is no loss to follow up as such until a subject stops treatment, dies or moves out of the country. However, for the present study, although nearly complete data were available from patients and rheumatologists at enrollment into the registry, data for random variables were missing at various time points in different patients. Furthermore, for patients enrolled in DANBIO after May 2005, follow up time was less than 48 months as the study observation time ended in May 2009.

Disease Activity

RA disease activity was assessed by the Disease Activity Score calculated on 4 variables including 28-joint counts and CRP (DAS28CRP4 scores) (20):

$$\text{DAS28CRP4} = 0.56 * \sqrt{\text{TJC28}} + 0.28 * \sqrt{\text{SJC28}} + 0.36 * \ln(\text{CRP} + 1) + 0.014 * \text{GH} + 0.96$$

Severity of RA disease activity was assessed by applying thresholds previously established for DAS28ESR4 (21) to the DAS28CRP4: remission ($\text{DAS28CRP4} < 2.6$), mild ($2.6 < \text{DAS28CRP4} \leq 3.2$), moderate ($3.2 < \text{DAS28CRP4} \leq 5.1$) or severe RA disease activity ($\text{DAS28CRP4} > 5.1$). We refer to the DAS28CRP4 as DAS28 henceforth.

RA Treatment Outcomes

Changes in RA symptoms from baseline were assessed using EULAR criteria for treatment response (22, 23). Trends in DAS28 scores were also evaluated over time to assess responses to treatment. Patients who were already in remission at baseline ($\text{DAS28} < 2.6$) (21) were excluded from the analyses ($n=82$).

Statistical Analyses

Patients were separated into 2 groups based on RA duration at baseline: early RA (duration ≤ 2 years), and established RA (duration > 2 years). All analyses were performed in each of these 2 patient groups separately.

Cross-sectional Differences between Sexes at Baseline—Summary statistics for men and for women were calculated as means and standard deviations (SD) for symmetrically distributed continuous variables, and medians with 25th and 75th percentiles, for non-normally distributed continuous variables. For categorical variables, proportions of patients within each patient group were computed. Sex differences in disease features at baseline were examined using (a) Chi-square tests to compare distributions of categorical variables between men and women; (b) the Mann-Whitney test and t-test were used for continuous variables.

Longitudinal Analyses of Treatment Outcomes in Men and Women (0–48 months)—Generalized Estimating Equations (GEE) models, with an independent correlation structure, were used to model differences in EULAR responses (categorized as a binary variable, i.e. no response vs. moderate/good response) between men and women over time (0–48 months), taking into account within-subject correlations in repeated measurements during the follow up. In the GEE models, follow-up time and sex (male sex as the referent group) were included as the main explanatory variables, adjusting for

baseline values of age, disease activity (DAS28), disease duration, anti-TNF therapy, methotrexate (yes/no) and prednisolone (yes/no). An interaction term (sex*follow-up time) was included to assess whether the time taken to achieve a moderate/good response was modified by sex. The mean values of the DAS28 scores were also plotted against follow up time for men and women, to visually assess any differences in trends in the raw data over time within each sex. In order to illustrate how the results of the GEE model translate into probabilities of a EULAR response, we computed probabilities of achieving a moderate/good EULAR response in men and women over time in early RA and in established RA, using the regression coefficients from the model, and the mean baseline values of age, DAS28 scores and RA duration. We also repeated the GEE analyses, using each DAS28 component as the outcome variable in the model separately, to determine which of these components may account for any observed association between EULAR response and sex.

Sensitivity Analyses

Since data were missing at different time points on a large proportion of subjects during the 48 months of study observation time, at each time point, we compared the mean DAS28 scores of the men and women who had data available at the next time-point, to those who did not, to assess whether there was any sex bias. Furthermore, we repeated the longitudinal analyses in the subset of patients on whom data were available at 48 months. We also investigated whether the probability of a significant HAQ response from baseline (i.e. $\Delta -0.22$) differed between men and women.

All statistical analyses were performed using the Stata software package (Release 11, StataCorp, College Station, Texas, USA).

Results

Baseline Characteristics of the Patient Population

A total of 2,129 RA patients were available from the DANBIO Registry for the present study. Among these patients, 476 (328 women and 148 men) had early RA and 1,653 (1,245 women and 408 men) had established RA. Overall, as shown in table 1, the early RA group had later disease onset compared to the group with long-standing RA and, as expected, were less likely to have developed radiographic erosions. Otherwise, the 2 groups had relatively similar disease features, and similar mean disease activity (DAS28, mean $\pm$ SD: 5.2 $\pm$ 1.1 in both groups), with the majority of patients having moderate to severe RA disease activity, i.e. DAS28 $>$ 3.2 (early RA: 96.2%, long-standing RA: 94.9%).

(a) Cross-sectional Differences between Sexes at Baseline—In both early and established RA, there were no significant sex differences in DAS28 scores, physician global scores, swollen joint counts and in the proportions of men and women with rheumatoid factor (RF) seropositivity and radiographic changes at baseline, when anti-TNF therapy was initiated (table 1). Men had significantly higher levels of CRP early in the disease course and were more likely to be current smokers or to have ever smoked, although these were statistically significant only in long-standing RA. Women had worse disability (HAQ-Disability Index), pain visual analogue scale (VAS), patient global scores, and fatigue VAS, and more tender joints; these differences appeared to be more pronounced in early RA, though not statistically significant. At baseline, approximately two thirds of the patients received concomitant methotrexate, and between one third and half of the patients were taking concomitant prednisolone. No important sex differences were observed at baseline in treatment patterns in early RA, whereas in long-standing RA, significantly more men were administered prednisolone compared to women. Similar proportions of men and women

were prescribed each of the different biologic anti-TNF therapies (infliximab, adalimumab and etanercept) at baseline.

(b) Longitudinal Analyses

Early RA: The observed proportions of men and women with good, moderate or no EULAR responses at each follow up (Figure 1) suggest that men were more likely to achieve better responses than women. In the GEE model with moderate/good EULAR response as the outcome (no response as the reference), the EULAR response differed significantly between men and women (table 2). In early RA, men were significantly more likely to have better responses over time compared to women ($p=0.003$). Furthermore, male sex was associated with a shorter time taken to achieve a good/moderate response, as shown by the interaction term (sex*follow up time) in the model ($p<0.0005$). In Figure 2a, the results from this model are further illustrated as probabilities of achieving a moderate/good response, with men expected to achieve a better response over time compared to women with similar baseline characteristics, irrespective of whether the patients were also taking methotrexate and/or prednisolone. These sex differences were also reflected in the observed trends of the mean DAS28 scores over the 48 months of follow up among men and women (Figure 3). There was a comparable and significant improvement in DAS28 scores in both men and women during the first 6 months after initiation of anti-TNF therapy irrespective of RA duration; after 6 months, the rate of improvement slowed down in both sexes, but was significantly better among men in the early RA group.

Established RA: Among patients with established RA, no association was found in the GEE models between sex and EULAR response or the time to achieve EULAR good/moderate response (table 2), as also shown in figure 3b.

DAS28 Components: Among the components of the DAS28 score, only CRP showed a pattern that resembled the EULAR responses when used as the outcome variable in the GEE model (data not shown). In early RA, men initially had higher observed CRP levels (table 1); after 12 months of follow up, the levels among women increased to levels higher than men; this difference was nevertheless not clinically significant. In established RA, on the other hand, the CRP levels were similar between men and women throughout the study period. Tender joint counts and patient global scores tended to be consistently lower among men in early RA, although the differences did not reach statistical significance. No sex differences were observed for these measures in established RA. Swollen joint counts were similar in men and women in both early and established RA.

Sensitivity analyses—At each time-point, the men and women who had data available at the next visit had similar mean DAS28 scores as those who had missing data at the next visit (data not shown). A GEE analysis restricted to those who had data at 48 months provided results similar to those presented for the entire dataset. The probability of a significant HAQ improvement was also higher among men, especially in the early RA group (data not shown).

Discussion

The present study of treatment responses to anti-TNF therapy among men and women in a large, observational cohort provides novel evidence that sex differences are present in early, but not in established RA. Within the DANBIO cohort, among patients who initiated therapy within 2 years of diagnosis, men achieved better and faster EULAR responses than women. This sex difference in treatment response was not seen in patients who initiated anti-TNF therapy more than 2 years after diagnosis. Thus, our results indicate that duration of the

disease prior to treatment being administered is important. Previous studies that investigated sex differences in treatment response have not addressed in detail the possible role of RA duration on sex modification of treatment responses, and a direct comparison of treatment responses by sex between early and established RA as presented in this paper, has not previously been reported to our knowledge. Studies of early RA cohorts performed by us (14) and by others (2, 7, 16) suggested that maleness is a predictor of better treatment responses and/or remission in early stages of the disease, which supports our findings of better responses among men with early RA in the DANBIO cohort. It was not known, however, whether these sex differences were specific to early RA or whether similar differences could be found among patients who have established RA when treatment is initiated. It has also not been investigated whether sex differences to treatment responses are influenced by the type of treatment administered – traditional DMARDs vs. biologic DMARDs. Nonetheless, although our knowledge about sex differences in treatment responses in RA is currently limited and based almost entirely on these recent studies, there is increasing evidence that men respond significantly better than women to both traditional DMARDs and anti-TNF therapy in early RA. In established RA, however, there were no sex differences in responses to anti-TNF therapy in the DANBIO cohort. Additional studies of established RA are warranted to replicate these findings.

Among the components of the DAS28 score, sex differences similar to those observed for EULAR responses were also found for CRP, although minor differences in tender joint counts and patient global scores may also have contributed to the observed differences in DAS28 and EULAR responses. The mechanism(s) responsible for the observed sex differences, and why these differences occur in early vs. established RA, are however still obscure. We speculate that there are intrinsic physiological sex differences that have a differential impact on the way men and women respond to treatment. For example, it has been demonstrated that men and women respond differently to low-dose aspirin, which is protective against heart-attack in men but not women, and protective against stroke in women but not men (24). We have previously observed that in early RA, women had worse progression of the disease over a 2-year period compared to men despite being on similar treatment (14), and similar findings have been reported by other groups (2, 6, 16). As to why men achieve better responses compared to women in early RA and not in established disease, we do not know. Interestingly, the observed trends in mean DAS28 scores in early and established RA suggest that women may experience similar responses to therapy irrespective of RA duration, and that the sex differences observed in early RA may be due to men responding better when treated in early rather than subsequent stages of the disease. We cannot, however, exclude the possibility that men may have a form of the disease that remits more often in the early course compared with women. Another interpretation of our findings may be that since DAS28 scores are highly dependent on pain perception, men may have a higher threshold for reporting joint tenderness and global health in early stages of the disease, but as disease duration increases, adaptive mechanisms relating to pain perception may be in operation, leading to a more similar reporting of symptoms between men and women. Nonetheless, given the current international effort on providing treatment in the early stages of RA (25), this difference between men and women is worth noting, and it is possible that eventually, sex-related response thresholds may need to be established to more effectively manage the disease in men and women.

In the NorDMARD (8) and GISEA (9) cohorts which were also observational, a significantly higher proportion of men had already achieved a good EULAR response or DAS28 remission by 6 months after initiation of anti-TNF therapy. In contrast to these studies, we found men and women to have a similar improvement in both early and established RA during the first 6 months. We have made similar observations in an independent early RA observational cohort (the Western Consortium of Practicing

Rheumatologists cohort) as previously reported (14) although the patients in that study were treated with traditional and not biologic DMARDs.

The present study has a number of limitations related to its observational nature and incomplete follow up. First, the patients were selected on the basis that they had initiated anti-TNF therapy and thus they represent patients with more severe RA. However, we are not aware of any selection bias in terms of sex as both men and women had similar disease activity and treatment at study baseline. Further, the DANBIO registry reflects routine practice of biological treatment, in real life settings in Denmark, with a >90% national coverage. Since anti-TNF therapy can only be prescribed and administered by hospital departments of rheumatology in Denmark, and the expenses are covered by the public health system, we expect minimal confounding by indication. Second, the number of patients in the early RA group, especially the number of men, was small and the results should be interpreted with caution. Third, by the end of the 4-year follow up period, approximately 80% of patients had missing data points at one or more follow up visits. However, there was no apparent sex bias in disease activity among the men and women with missing data, and the missing data appeared with similar frequencies among men and women.

In summary, our results corroborate previous findings that men respond better to treatment than women in early RA, and provide novel evidence that such sex differences are observed in early, but not established RA. Thus, if sex differences in treatment responses become apparent only when treatment is administered in early stages of the disease, then perhaps all studies comparing responses to treatment over time between men and women should take into consideration the duration of the disease at the time when treatment is initiated. Our results further demonstrate that when a cohort of patients with established RA is adjusted for confounders and for accumulated sex differences in various disease features present at the start of follow up, no sex difference is expected to remain during follow up. Hence, using cohorts of patients with varying RA durations at initiation of therapy is not recommended when the aim is to study sex differences in treatment responses.

Acknowledgments

We thank our collaborators from the Rheumatology departments in the following hospitals in Denmark for contributing data from their RA patients to the DANBIO registry: Ålborg, Århus, Esbjerg, Frederiksberg, Gentofte, Glostrup, Gråsten, Hjørring, Holbæk, Holstebro, Horsens, Hørsholm, Kolding, Næstved/Nykøbing Falster, Odense, Randers, Rigshospitalet, Roskilde/Køge, Silkeborg, Slagelse, Svendborg/Fåborg, Vejle and Viborg.

We thank Niels Steen Krogh for assistance with extracting DANBIO data.

We also thank Dr. Ginny Gildengorin at the Children's Hospital Oakland Research Institute for statistical advice.

Grant supporter(s) – Damini Jawaheer, Ph.D. is supported by a Career Development Award (K01AR053496) from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). The DANBIO Registry is supported by the hospital owners and by grants from Abbott, Bristol-Meyers Squibb, Roche, Schering-Plough/MSD, UCB-Nordic and Wyeth/Pfizer. The pharmaceutical companies had no influence on the study design, data analyses and interpretation or the writing on the manuscript.

References

1. Silman, AJ.; Hochberg, MC. Epidemiology of the rheumatic diseases. 2 ed.. Oxford ; New York: Oxford University Press; 2001. Rheumatoid Arthritis; p. 31-70.
2. Forslind K, Hafstrom I, Ahlmen M, Svensson B. Sex: a major predictor of remission in early rheumatoid arthritis? *Ann Rheum Dis.* 2007; 66(1):46–52. [PubMed: 17158139]
3. Ahlmen M, Svensson B, Albertsson K, Forslind K, Hafstrom I. Influence of gender on assessments of disease activity and function in early rheumatoid arthritis in relation to radiographic joint damage. *Ann Rheum Dis.* 2010; 69(1):230–233. [PubMed: 19158113]

4. Leeb BF, Haindl PM, Maktari A, Nothnagl T, Rintelen B. Disease activity score-28 values differ considerably depending on patient's pain perception and sex. *J Rheumatol.* 2007; 34(12):2382–2387. [PubMed: 17985407]
5. Sokka T, Toloza S, Cutolo M, Kautiainen H, Makinen H, Gogus F, et al. Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA Study. *Arthritis Res Ther.* 2009; 11(1):R7. [PubMed: 19144159]
6. Iikuni N, Sato E, Hoshi M, Inoue E, Taniguchi A, Hara M, et al. The influence of sex on patients with rheumatoid arthritis in a large observational cohort. *J Rheumatol.* 2009; 36(3):508–511. [PubMed: 19208610]
7. Makinen H, Hannonen P, Sokka T. Sex: a major predictor of remission as measured by 28-joint Disease Activity Score (DAS28) in early rheumatoid arthritis? *Ann Rheum Dis.* 2008; 67(7):1052–1053. [PubMed: 18556449]
8. Kvien TK, Uhlig T, Odegard S, Heiberg MS. Epidemiological aspects of rheumatoid arthritis: the sex ratio. *Ann N Y Acad Sci.* 2006; 1069:212–222. [PubMed: 16855148]
9. Mancarella L, Bobbio-Pallavicini F, Ceccarelli F, Falappone PC, Ferrante A, Malesci D, et al. Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study. *J Rheumatol.* 2007; 34(8):1670–1673. [PubMed: 17611987]
10. Sokka T, Hetland ML, Makinen H, Kautiainen H, Horslev-Petersen K, Luukkainen RK, et al. Remission and rheumatoid arthritis: Data on patients receiving usual care in twenty-four countries. *Arthritis Rheum.* 2008; 58(9):2642–2651. [PubMed: 18759292]
11. Burmester GR, Ferraccioli G, Flipo RM, Monteagudo-Saez I, Unnebrink K, Kary S, et al. Clinical remission and/or minimal disease activity in patients receiving adalimumab treatment in a multinational, open-label, twelve-week study. *Arthritis Rheum.* 2008; 59(1):32–41. [PubMed: 18163417]
12. van der Heijde D, Klareskog L, Landewe R, Bruyn GA, Cantagrel A, Durez P, et al. Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. *Arthritis Rheum.* 2007; 56(12):3928–3939. [PubMed: 18050208]
13. Hyrich KL, Watson KD, Silman AJ, Symmons DP. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. *Rheumatology (Oxford).* 2006; 45(12):1558–1565. [PubMed: 16705046]
14. Jawaheer D, Maranian P, Park G, Lahiff M, Amjadi SS, Paulus HE. Disease progression and treatment responses in a prospective DMARD-naïve seropositive early rheumatoid arthritis cohort: does gender matter? *J Rheumatol.* 2010; 37(12):2475–2485. [PubMed: 20889597]
15. Tengstrand B, Ahlmen M, Hafstrom I. The influence of sex on rheumatoid arthritis: a prospective study of onset and outcome after 2 years. *J Rheumatol.* 2004; 31(2):214–222. [PubMed: 14760787]
16. Kuiper S, van Gestel AM, Swinkels HL, de Boo TM, da Silva JA, van Riel PL. Influence of sex, age, and menopausal state on the course of early rheumatoid arthritis. *J Rheumatol.* 2001; 28(8):1809–1816. [PubMed: 11508583]
17. Karlsson JA, Kristensen LE, Kapetanovic MC, Gulfe A, Saxne T, Geborek P. Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register. *Rheumatology (Oxford).* 2008; 47(4):507–513. [PubMed: 18304941]
18. Hetland ML. DANBIO--powerful research database and electronic patient record. *Rheumatology (Oxford).* 2011; 50(1):69–77. [PubMed: 21148154]
19. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum.* 1988; 31(3):315–324. [PubMed: 3358796]
20. <http://www.das-score.nl/www.das-score.nl/>
21. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a

- prospective longitudinal study of patients with rheumatoid arthritis. *Arthritis Rheum.* 1995; 38(1): 44–48. [PubMed: 7818570]
22. van Gestel AM, Prevoo ML, van't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. *Arthritis Rheum.* 1996; 39(1):34–40. [PubMed: 8546736]
23. van Gestel AM, Haagsma CJ, van Riel PL. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. *Arthritis Rheum.* 1998; 41(10):1845–1850. [PubMed: 9778226]
24. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. *N Engl J Med.* 2005; 352(13):1293–1304. [PubMed: 15753114]
25. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. *Ann Rheum Dis.* 2010; 69(9):1580–1588. [PubMed: 20699241]

(a)

(b)

Figure 1.

The observed proportions of (a) women and (b) men with good, moderate or no EULAR responses, as well as sample sizes are shown at each follow up. A EULAR response could not be assessed for some patients who were missing DAS28 data at baseline; hence, sample sizes are smaller than those in Figure 3.

(a)

(b)

Figure 2.

Expected probabilities of achieving a moderate/good EULAR response over time are shown, as an example, in men vs. women in (a) early and (b) established RA, using mean baseline values of age, DAS28 scores and RA duration computed for early and established disease - based on the GEE model in table 2.

Figure 3.

The observed mean values of the DAS28 scores among men (solid line) and women (broken line) in early vs. established RA and sample sizes at each follow up are shown.

Table 1

Summary of disease characteristics at baseline by RA duration and Sex

Baseline characteristics	RA duration ≤ 2 years			RA duration >2 years		
	Men (n = 148)	Women (n = 328)	p-value	Men (n = 408)	Women (n = 1,245)	p-value
Age at diagnosis (yrs)	51.3±13.2	50.1±14.5	0.37	44.6±12.8	43.2±15.0	0.07
Disease duration (yrs)	1.23±0.74	1.21±0.70	0.76	13.1±8.9	13.8±10.0	0.18
Radiographic erosions, %	51.9	49.1	0.69	84.2	81.9	0.49
RF seropositivity, %	66.3	58.5	0.20	85.4	81.3	0.18
RA Disease Activity:						
Mild, %	6.3	2.6	0.16	5.7	4.8	0.43
Moderate, %	43.1	43.3		40.7	38.0	
Severe, %	50.7	54.1		53.6	57.2	
DAS28	5.1±1.2	5.2±1.1	0.45	5.2±1.2	5.3±1.1	0.26
Tender joint count	8 (4–16)	10 (5–16)	0.13	8 (4–14)	9 (5–15)	0.02
Swollen joint count	6 (3–11)	6 (4–10)	0.96	7 (4–11)	7 (4–11)	0.74
CRP	15 (7–45)	11 (5–31)	0.03	18 (8–36)	17 (8–35)	0.11
Patient global score	59.7±21.5	64.1±23.1	0.05	61.1±21.7	62.3±23.0	0.32
Physician global score	48.9±21.7	47.9±20.3	0.65	47.1±21.2	47.4±21.2	0.79
HAQ-DI	1.0±0.7	1.3±0.7	0.0001	1.1±0.8	1.5±0.8	<0.00005
Pain VAS	55.1±22.7	58.8±23.7	0.12	57.1±21.9	58.1±22.4	0.45
Fatigue VAS	59.3±22.8	68.3±21.2	0.35	47.1±22.3	50.3±25.8	0.60
Smoking history						
Current smoker, %	42.9	34.3	0.33	43.3	31.8	0.04
Ever smoker, %	71.4	65.7	0.51	80.4	59.5	<0.0005
Methotrexate, %	71	65.2	0.22	65.9	65.8	0.96
Prednisolone, %	40.5	35.4	0.28	52.9	40.9	<0.0005
Anti-TNF therapy						
Infliximab, %	42.6	43	0.97	36.8	40.4	0.37
Adalimumab, %	31.1	31.7		35.3	34.4	
Etanercept, %	26.4	25.3		27.9	25.2	

Results are shown as mean±SD or medians (inter-quartile range, IQR), unless otherwise indicated.

Table 2

Predictors of moderate/good EULAR response in early and established RA (GEE model)

Outcome variable: “moderate/good EULAR response”	RA 2 years		RA > 2 years	
	Coefficient (95% C.I.)	p value	Coefficient (95% C.I.)	p value
Sex [‡]	0.93 (0.31, 1.55)	0.003	0.02 (−0.32, 0.36)	0.90
Follow up (months)	0.08 (0.05, 0.12)	<0.0005	0.02 (0.009, 0.04)	0.001
Sex*Follow up	−0.08 (−0.12, −0.04)	<0.0005	0.003 (−0.01, 0.02)	0.70
Age [§]	−0.01 (−0.02, 0.003)	0.14	−0.002 (−0.01, 0.006)	0.62
RA duration [§]	0.18 (−0.14, 0.49)	0.27	−0.002 (−0.01, 0.008)	0.70
DAS28 [§]	0.46 (0.25, 0.67)	<0.0005	0.62 (0.52, 0.72)	<0.0005
Anti-TNF therapy [§]	0.05 (−0.22, 0.32)	0.72	0.18 (0.05, 0.30)	0.006
Methotrexate [§]	0.76 (0.33, 1.19)	0.001	0.25 (0.05, 0.46)	0.01
Prednisolone [§]	−0.32 (−0.72, 0.08)	0.11	−0.31 (−0.50, −0.12)	0.002
Intercept	−2.28 (−3.83, −0.72)	0.004	−2.36 (−3.15, −1.57)	<0.0005

[‡]The referent group for sex was male.

[§]For these covariates, only baseline values were adjusted for in the GEE model.